Dr. Marian Gorecki - Co-Chair, Head of R&D and one of the Founders of UDM, Vanir & Valin, three entities focusing on the development and licensing-out of first and second generation Biosimilars.
Dr. Gorecki received a PhD from the Weizmann Institute of Science and was a post-graduate fellow in Biology Department at the Massachusetts Institute of Technology (MIT) in Cambridge, Mass, USA. In 1976, he was appointed Senior Research Scientist and Associate Professor at the Weizmann Institute. In 1980, Dr. Gorecki co-founded BioTechnology General Corp. and was responsible for its R&D group. He was appointed Senior Vice President, Chief Technical Officer for BTG Corp. and Managing Director for BTG IL Ltd.
Dr. Gorecki has more than 18 patents and published 75 scientific papers in the area of protein chemistry, molecular biology and biotechnology. After an early retirement from BTG Dr. Gorecki formed Mediwound, a company that develops treatment for burn debridement. Dr. Gorecki is a consultant to the Clal Biotechnology Industries and seats on the Board of several other Biotechnology companies. He recently received a prestigious award for most outstanding scientist for his contribution to the biotechnology sector.
 

Dr. Jacob Hartman – Dr. Hartman is the Vice President of R&D at Valin Technologies Ltd.
Dr. Hartman received a PhD in Molecular Biology and a post- graduate fellow in the Department of Microbiology and Immunology and Molecular Biology Institute at the University of California, Los Angeles, USA. Dr. Hartman has 36 Publications in first tier scientific journals and 32 patents and seats on several Boards of Biotechnology companies.
Prior to joining Valin, Dr. Hartman was the Director of R&D at SciGen Ltd responsible for the comprehensive characterization of Sci-B-Vac, the hepatitis B surface antigen vaccine, GCSF technology transfer coordination and validation and supports of the manufacturing facility in Pune, India.
Prior to joining SciGen, Dr Hartman was with Biotechnology General (now Ferring) where he was responsible for biopharmaceutical project development, project evaluation and strategic planning.
Dr. Hartman was successfully involved in the development of recombinant human insulin, carboxipeptidase B, interferon’s a and ß and PEGylated Uricase and the scaling-up production processes and technology transfer.
 

Dr. Shmulik Hess - is the CEO of Valin Technologies Ltd and a Board member of Vanir Pte Ltd. Dr. Hess recived his PhD in Pharmacology and Pharmaceuticals Science from the Hebrew University, and was a research fellow at the Harvard MIT division of health science and technology, Cambridge, Massachusetts. Dr. Hess remains a research affiliate at Harvard MIT health division. Prior to joining Valin Technologies Dr. Hess was CEO and co-founder of Active P a biotechnology startup involved in the development of oral available peptidic drugs for the treatment of pain and metabolic disease. Dr. Hess has gained vast experience with peptide and protein pharmacokinetics and dynamics as well as immunobiology and tissue engineering. Dr. Hess has gained several Publications in scientific journals and patents.
 

Mr. Saul Mashaal Phmb, MBA - Co-Chair and Head of Corporate Business Development and one of the Founders of UDM, Vanir & Valin, three entities focusing on the development and licensing-out of first and second generation Biosimilars and is the Chairman of Acertus Pharma LLC a consulting firm in the Biopharmaceutical sector of the Healthcare Industry.
Mr Mashaal has over 40 years experience in the Biopharmaceutical industry. He started his career with Syntex Laboratories Ltd (now Roche) with the business development of systemic steroids and NSAID products. In 1973, Mr Mashaal joined the 3M Company to head the Clinical Research Group. Subsequently he was given responsibility for the management of 3M Health & Sciences subsidiary companies in Latin America and the Caribbean’s and in 1980 the International Business Development of the Health & Science Sector. In 1988 he founded SciTech Genetics for the development, thru networking with Biopharmaceutical companies and Research Institutions, Biotechnology derived products and diagnostics for human healthcare and Acertus Pharma for the distribution and marketing of Biopharmaceutical products.
In 2002 Mr. Mashaal transferred the portfolio of biotechnology products to a newly formed Singapore Company SciGen Ltd. SciGen listed in the Australian Stock Exchange (ASX) and was subsequently acquired by Bioton S.A. Mr. Mashaal remained as its Chairman & CEO. Mr. Mashaal left SciGen Ltd in April 2009 to form Valin, a research & development Biotechnology Company focusing on first and second generation of Biosimilars. Another entity, Vanir, is the commercial arm for licensing-out biotechnology derived products.
During the course of his career, Mr. Mashaal was instrumental in the building of major Biotechnology Manufacturing facilities in several countries, a total Capex value of US$550 Million dollars. Mr. Mashaal has a degree in Pharmacy from the Sorbonne and MBA from Windsor University.
 

Mr. Yehuda Zelig, MBA: Mr. Zelig is the Co-Chair and Director of Operations and one of the Founders of UDM, Vanir & Valin, three entities focusing in the development and licensing-out of first and second generation Biosimilars.
Prior to this he served as Managing Director of SciGen IL Ltd and SVP global operations, where he established a state of the art vaccine manufacturing facility as well as a biologic manufacturing facility in India. Prior to joining Scigen Mr. Zelig served as vice president at Biorest LTD. A company developing a drug for the treatment of restenosis, Biorest has recently completed a successful phase II study. Mr. Zelig was Vice President Manufacturing with Biotechnology General IL responsible for the management of manufacturing development and scale up of biotechnology products. He planned and established the biotechnology GMP manufacturing plant for bulk and final sterile products and managed the preparation for FDA, CE, GB and Canadian regulatory authority inspections and Biorest Ltd as Senior Vice President where he was responsible for the establishment of a pilot plant developing cardiovascular drug, transfer technology of process and analytical methods, planning, establishment and implementation of pharmaceutical manufacturing plant under GMP rules, development and production of product for pre-clinical and clinical studies and establishment of a Quality management system.
Mr. Zelig has a BSc in Agriculture, an MSc in Life Sciences and a MBA from prestigious Universities and seats on several Boards of Biopharmaceutical companies.